palivizumab

Product Name: palivizumab
CAS No.: 188039-54-5
Chemical Name: palivizumab
Synonyms: Synagis;palivizumab;Synagis|||MEDI 493;Research Grade Palivizumab;Research Grade Palivizumab(DVV02801)
CBNumber: CB11386500
Formula Weight: 0
MOL File: Mol file

More

Less

palivizumab Property

storage temp.: Store at -20°C
form: Liquid
color: Colorless to light yellow

More

Less

Safety

Hazardous Substances Data: 188039-54-5(Hazardous Substances Data)

More

Less

Hazard and Precautionary Statements (GHS)

More

Less

palivizumab Chemical Properties,Usage,Production

Uses

Palivizumab (MEDI 493) is a humanized monoclonal antibody against respiratory syncytial virus (RSV). Palivizumab can bind to RSV F protein with a Kd value of 1.4 nM. Palivizumab can prevent respiratory syncytial virus infection in cotton mice[1].

Indications

Palivizumab (Synagis) is a humanized monoclonal antibody directed against the highly conserved A antigenic site of the F protein on the surface of RSV. It contains 95% human and 5% murine antibody sequences and tends to have little immunogenicity in humans. Palivizumab is composed of the human framework region of the IgG-1κ-chain joined to the antigen-binding regions of a mouse monoclonal antibody. Palivizumab neutralizes RSV and inhibits its ability to fuse with host cell membranes. Resistant strains of RSV have been derived in vitro but have not been found in clinical isolates to date.

Clinical Use

Palivizumab is used to prevent serious lower respiratory tract infection due to RSV. It is used only in high-risk children who are younger than 24 months of age and have bronchopulmonary dysplasia or chronic lung disease that required treatment in the previous 6 months. It is also indicated for premature infants (less than 32 weeks’ gestation) until the age of 6 to 12 months. Palivizumab can reduce the incidence of RSV-related hospitalization by approximately half.The safety and efficacy of palivizumab in the treatment of RSV disease have not been established.

Side effects

Serious adverse reactions caused by palivizumab are rare.Mild erythema and pain may occur at the injection site.Although no anaphylactoid reactions have been reported to date, the possibility of this reaction exists because palivizumab is a protein.

in vivo

Palivizumab (0.625-5 mg/kg (i.m.) or 0.312-10 mg/kg (i.v.); single dose) can prevent respiratory syncytial virus infection in cotton mice^[1]. Palivizumab (0.05 mg/kg; single dose; intranasally administered)can prevent RSV infection in mice^[2]. Palivizumab (15 mg/kg; single dose; s.c.) can inhibit RSV induced airway neurogenic inflammation in rats^[3].

Animal Model:	The cotton rat model of RSV infection^[1].
Dosage:	0.625-5 mg/kg (i.m.) or 0.312-10 mg/kg (i.v.)
Administration:	Intramuscular injection (i.m.) or intravenous injection (i.v.); single dose
Result:	Reduced virus replication and did not cause RSV infection or pathological increase in both initial and secondary attacks.

Animal Model:	BALB/c mice^[2].
Dosage:	0.05 mg/kg
Administration:	Intranasally administered; single dose
Result:	Reduced the RSV load.

Animal Model:	Capsaicin-induced neurogenic inflammation in the airways of rats^[3].
Dosage:	15 mg/kg
Administration:	Subcutaneous injection (s.c.); single dose
Result:	Reduced neurogenic extravasation and neurogenic inflammation.

References

[1] Johnson S, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis. 1997 Nov;176(5):1215-24. DOI:10.1086/514115
[2] Jacobino SR, et al. Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo. MAbs. 2018 Apr;10(3):453-462. DOI:10.1080/19420862.2018.1433974
[3] Piedimonte G, et al. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res. 2000 Mar;47(3):351-6. DOI:10.1203/00006450-200003000-00011

palivizumab Preparation Products And Raw materials

Raw materials

Preparation Products

More

Less

palivizumab Suppliers

CHINA 24 India 1 United States 2 Global 27

Wuhan Sunrise Technology Development Co., Ltd.

Tel: 27-027-83314682 13554138826
Fax: +86 (27) 8331-4682
Email: whsrtech@vip.163.com
Country: China
ProdList: 246
Advantage: 62

Beijing HuaMeiHuLiBiological Chemical

Tel: 010-56205725
Fax: 010-65763397
Email: waley188@sohu.com
Country: China
ProdList: 12335
Advantage: 58

Shanghai EFE Biological Technology Co., Ltd.

Tel: 021-65675885 18964387627
Fax: 021-65675885
Email: info@efebio.com
Country: China
ProdList: 9803
Advantage: 58

Shanghai YuanYe Biotechnology Co., Ltd.

Tel: 021-61312847; 18021002903
Fax: QQ:3008007432
Email: 3008007409@qq.com
Country: China
ProdList: 71826
Advantage: 60

ShangHai Biochempartner Co.,Ltd

Tel: 177-54423994 17754423994
Fax: QQ:2853530913
Email: 2853530910@QQ.com
Country: China
ProdList: 8000
Advantage: 62

Guangzhou Hongyuan Chemical Co.,Ltd

Tel: 15817493340
Email: 981810490@qq.com
Country: China
ProdList: 1566
Advantage: 58

Wuhan Chemstan Biotechnology Co., Ltd.

Tel: 027-65317797 15926423062
Fax: QQ：422450190
Email: 422450190@qq.com
Country: China
ProdList: 10308
Advantage: 58

Hubei Kele Fine Chemical Co., Ltd

Tel: 027-59101668 19945030958
Fax: 027-59101668
Email: 2881924765@qq.com
Country: China
ProdList: 7938
Advantage: 58

Wuhan Yingnuo Pharmaceutical Technology Co., Ltd.

Tel: 15387063101
Email: 2881924050@qq.com
Country: China
ProdList: 9960
Advantage: 58

TargetMol Chemicals Inc.

Tel: 4008200310
Email: marketing@tsbiochem.com
Country: China
ProdList: 24961
Advantage: 58

Biolab Reagents

Tel: 027-65279366 18108604356
Email: products@biolabreagent.com
Country: China
ProdList: 9868
Advantage: 58

Wuhan Jingkangen Biomedical Technology Co., Ltd

Tel: 13720134139 086-15871494362 13720134139
Email: orders@jknbiochem.com
Country: China
ProdList: 6614
Advantage: 58

Shanghai jerryxing Biomedical Technology Co., Ltd

Tel: 17721492509; 17721492509
Email: 643638326@qq.com
Country: China
ProdList: 4971
Advantage: 58

Changsha Fuzhen Biotechnology Co.，LTD

Tel: 0731-13823398 15111215862
Email: 313359644@qq.com
Country: China
ProdList: 4161
Advantage: 58

Wanxin Biotechnology (Jiaxing) Co., LTD

Tel: 0573-83568680 18057391398
Email: 3956524501@qq.com
Country: China
ProdList: 1442
Advantage: 58

Atagenix Laboratories

Tel: 027-87008169 17762441161
Email: info@atagenix.com
Country: China
ProdList: 10001
Advantage: 58

Sangon Biotech (Shanghai) Co.,Ltd.

Tel: 400-821-026
Email: Sales@sangon.com
Country: China
ProdList: 6710
Advantage: 58

AntibodySystem Laboratories SAS

Tel: 33175446423
Email: support@antibodysystem.com
Country: China
ProdList: 6739
Advantage: 58

Biosynth Biological Technology (Suzhou) Co Ltd

Tel: 51288865780
Email: sales@biosynth.com
Country: China
ProdList: 6051
Advantage: 58

Cell Sciences

Tel: 9785721070
Email: info@cellsciences.com
Country: China
ProdList: 6308
Advantage: 58

Hualan Gene Engineering Co., Ltd.

Tel
Country: CHINA
ProdList: 8
Advantage: 58

BioEasy Biotech (Shenzhen) Co., Ltd.

Tel: 18666024416
Country: CHINA
ProdList: 185
Advantage: 58

Guangzhou Chuangze Biotechnology Co., Ltd.

Tel: 18312220236
Country: CHINA
ProdList: 178
Advantage: 58

Proteintech China

Tel: --
Fax: --
Email: Proteintech-CN@ptglab.com
Country: CHINA
ProdList: 6290
Advantage: 58

188039-54-5, palivizumabRelated Search:

Follicle stimulating hormone Secukinumab Daratumumab OMALIZUMAB Dulaglutide Trastuzumab emtansine Ranibizumab Immunoglobulin G4,anti-(human integrin R4) (human-mouse monoclonal AN100226 c4-chain),disulfide with human-mouse monoclonal AN100226 light chain,dimer Eculizumab Panitumumab Trastuzumab Matuzumab ticilimumab tremelimumab CNTO 148 Aflibercept abciximab nimotuzumab belimumab

palivizumab

Research Grade Palivizumab(DVV02801)

Synagis

Synagis|||MEDI 493

Research Grade Palivizumab

188039-54-5